Vutrisiran sodium

• CAT Number: I040117
• Molecular Formula: C530H671F9N171Na44O323P43S6
• Molecular Weight: 17311.72
• Purity: ≥95%

Vutrisiran sodium (Cat No.: I040117 ) is an investigational RNA interference (RNAi) therapeutic designed to reduce the production of transthyretin (TTR) protein. By silencing the TTR gene, vutrisiran sodium aims to treat transthyretin amyloidosis, a rare and progressive disease caused by the accumulation of misfolded TTR in tissues, leading to organ damage. Vutrisiran sodium is delivered via subcutaneous injection and has shown promise in clinical trials for improving neurological function and quality of life in patients with hereditary ATTR amyloidosis.

Reference

[1]. Bahru A Habtemariam, et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2021 Feb;109(2):372-382.
[Content Brief]